Lim, E. Et Al. 2022. An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer. Breast Cancer Research and Treatment , vol.195, no.3 , 275-287.

Lim, E., Boyle, F., Okera, M., Loi, S., SEZGİN GÖKSU, S., van Hal, G., ... Chapman, S. C.(2022). An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer. Breast Cancer Research and Treatment , vol.195, no.3, 275-287.

Lim, Elgene Et Al. "An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer," Breast Cancer Research and Treatment , vol.195, no.3, 275-287, 2022

Lim, Elgene Et Al. "An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer." Breast Cancer Research and Treatment , vol.195, no.3, pp.275-287, 2022

Lim, E. Et Al. (2022) . "An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer." Breast Cancer Research and Treatment , vol.195, no.3, pp.275-287.

@article{article, author={Elgene Lim Et Al. }, title={An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer}, journal={Breast Cancer Research and Treatment}, year=2022, pages={275-287} }